CoChat

Suppression of Niacin-induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

Lai, E, De Lepeleire, I, Crumley, T M, Liu, F, Wenning, L A, Michiels, N, Vets, E, O'Neill, G, Wagner, J A, Berkwits, M · 2007 · Clinical Pharmacology & Therapeutics
Cited by 152

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Niacin (nicotinic acid) reduces cardiovascular events in patients with dyslipidemia. However, symptoms associated with niacin-induced vasodilation (e.g., flushing) have limited its use. Laropiprant is a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1), which may mediate niacin-induced vasodilation. The aim of this proof-of-concept study was to evaluate the effects of laropiprant (vs placebo) on niacin-induced cutaneous vasodilation. Coadministration of laropiprant 30, 100, and 300 mg with extended-release (ER) niacin significantly lowered flushing symptom scores (by approximately 50% or more) and also significantly reduced malar skin blood flow measured by laser Doppler perfusion imaging. Laropiprant was effective after multiple doses in reducing symptoms of flushing and attenuating the increased malar skin blood flow induced by ER niacin. In conclusion, the DP1 receptor antagonist laropiprant was effective in suppressing both subjective and objective manifestations of niacin-induced vasodilation. Clinical Pharmacology & Therapeutics (2007) 81, 849–857. doi:10.1038/sj.clpt.6100180; published online 28 March 2007 TRIAL REGISTRATION: This study has been registered at clinicaltrials.gov on 9/19/2007 (NCT00533312).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.clpt.6100180

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 152

Metadata

Authors
Lai, E., De Lepeleire, I., Crumley, T. M., Liu, F., Wenning, L. A., Michiels, N., Vets, E., O'Neill, G., Wagner, J. A., & Berkwits, M.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2007-03-28
Volume
81
Issue
6
Pages
849-857
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2036706177
Cited by
152
References
4
FWCI
14.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suppression of Niacin-induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1. https://app.cochat.ai/papers/10.1038/sj.clpt.6100180
The paper
Lai, E., De Lepeleire, I., Crumley, T. M., Liu, F., Wenning, L. A., Michiels, N., Vets, E., O'Neill, G., Wagner, J. A., & Berkwits, M. (2007). Suppression of Niacin-induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/sj.clpt.6100180

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.